# A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

> **NCT07712523** · PHASE2 · RECRUITING · sponsor: **E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Adult Subjects With Non-Segmental Vitiligo

## Interventions

- **DRUG:** QY201 Tablets(5mg）
- **DRUG:** QY201 Tablets（10mg）
- **DRUG:** QY201 Tablets（20mg）
- **DRUG:** QY201 Placebo Tablets

## Key facts

- **NCT ID:** NCT07712523
- **Lead sponsor:** E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712523, "A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*